A Phase I/II, Multi-Center, Open-Label Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 10 Feb 2015
At a glance
- Drugs BGT 226 (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 13 Oct 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 13 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Mar 2008 New trial record.